title: Fulvestrant ('Faslodex')--a new hormonal treatment for advanced breast cancer.
abstract: In patients with hormone receptor-positive advanced breast cancer (ABC), endocrine therapy is as effective as cytotoxic chemotherapy but is better tolerated. Most breast cancers are hormone responsive, but eventually develop resistance to individual endocrine agents. However, changing to a different type of endocrine therapy when resistance develops can circumvent this problem and delay the need for cytotoxic chemotherapy. Such chemotherapy can have a major impact on patient's quality of life, and for this reason is generally considered to be a last option for breast cancer patients. Fulvestrant ('Faslodex') is a new type of endocrine therapy with a different mode of action to existing treatments. It is at least as effective as the third-generation aromatase inhibitor (AI) anastrozole or letrozole in the treatment of postmenopausal women with advanced, tamoxifen-resistant breast cancer. Fulvestrant also appears to be effective after treatment with non-steroidal AIs. Fulvestrant is well tolerated and provides a further option in the endocrine treatment of ABC.
authors.affiliation: The George Washington University Breast Care Center, Washington, DC, USA. JeanLynn1@aol.com
authors.forename: Jean
authors.initials: J
authors.lastname: Lynn
mesh_terms: D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D017698:Postmenopause; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D000077267:Fulvestrant; D004958:Estradiol